SLDBSolid Biosciences Inc.

Nasdaq solidbio.com


$ 8.88 $ -0.06 (-0.67 %)    

Friday, 16-Aug-2024 15:59:58 EDT
QQQ $ 475.24 $ 0.61 (0.13 %)
DIA $ 406.80 $ 0.86 (0.21 %)
SPY $ 554.24 $ 1.24 (0.22 %)
TLT $ 97.41 $ 0.34 (0.35 %)
GLD $ 231.90 $ 5.08 (2.24 %)
$ 8.87
$ 8.86 x 200
-- x --
-- - --
$ 1.81 - $ 15.05
243,010
na
363.09M
$ 1.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-13-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 04-27-2022 03-31-2022 10-Q
11 03-14-2022 12-31-2021 10-K
12 11-03-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-15-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-13-2019 03-31-2019 10-Q
23 03-13-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 08-10-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-solid-biosciences-lowers-price-target-to-15

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $18 ...

 hc-wainwright--co-reiterates-buy-on-solid-biosciences-maintains-16-price-target

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.

 solid-biosciences-q2-eps-061-beats-067-estimate

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0...

 jp-morgan-upgrades-solid-biosciences-to-overweight-raises-price-target-to-15

JP Morgan analyst Anupam Rama upgrades Solid Biosciences (NASDAQ:SLDB) from Neutral to Overweight and raises the price targe...

 leerink-partners-upgrades-solid-biosciences-to-outperform-maintains-price-target-to-12

Leerink Partners analyst Joseph Schwartz upgrades Solid Biosciences (NASDAQ:SLDB) from Market Perform to Outperform and main...

 piper-sandler-reiterates-overweight-on-solid-biosciences-maintains-20-price-target

Piper Sandler analyst Biren Amin reiterates Solid Biosciences (NASDAQ:SLDB) with a Overweight and maintains $20 price target.

 jp-morgan-maintains-neutral-on-solid-biosciences-lowers-price-target-to-10

JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Neutral and lowers the price target from $12 ...

 hc-wainwright--co-reiterates-buy-on-solid-biosciences-maintains-16-price-target

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.

 barclays-maintains-overweight-on-solid-biosciences-lowers-price-target-to-18

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $21 ...

 solid-biosciences-q1-eps-064-inline

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.64) per share which met the analyst consensus estimate. This i...

 solid-biosciences-receives-rare-pediatric-disease-designation-from-the-fda-for-duchenne-muscular-dystrophy-gene-therapy-candidate-sgt-003

Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and card...

 william-blair-initiates-coverage-on-solid-biosciences-with-outperform-rating-announces-price-target-of-40

William Blair analyst Tim Lugo initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces ...

 barclays-maintains-overweight-on-solid-biosciences-raises-price-target-to-21

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $8 t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION